NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) issued its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $8.59 million for the quarter, compared to the consensus estimate of $11.18 million. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The firm's quarterly revenue was up 776.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) EPS. View Synergy Pharmaceuticals' Earnings History.

8 equities research analysts have issued 1 year price objectives for Synergy Pharmaceuticals' shares. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $8.8125 in the next year. This suggests a possible upside of 363.8% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 54,868,105 shares, a decrease of 12.8% from the June 15th total of 62,939,216 shares. Based on an average daily volume of 3,251,186 shares, the short-interest ratio is presently 16.9 days. Currently, 22.3% of the company's shares are short sold. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), Mallinckrodt (MNK), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), IMMURON Ltd/S (IMRN), Corcept Therapeutics (CORT), G1 Therapeutics (GTHX), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Innoviva (INVA) and TherapeuticsMD (TXMD).

News stories about SGYP stock have trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.45 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.90.

Synergy Pharmaceuticals has a market capitalization of $468.81 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]